How to Speed Up Drug Development with AI With: Tom Neyarapally
Tom Neyarapally, CEO of Archetype Therapeutics, explains why drug discovery remains slow despite major technological advances. He highlights that while access to molecular profiling, patient clinical data, advanced AI/ML tools, and scalable compute power have transformed the field, traditional workflows remain fragmented. Neyarapally advocates for a patient-centric approach—starting with well-characterized patient cohorts and using AI to screen drugs that can move them from illness toward wellness. This method, coupled with repurposing existing safe drugs, can dramatically shorten proof-of-concept timelines.
Episode Contents:
Key Takeaways
- Drug discovery delays stem from disjointed processes
- AI enables patient-centric screening for faster insights
- Repurposing safe drugs can speed up proof-of-concept trials
Transcript Summary
Why is drug discovery still so slow?
Progress requires the right data, AI/ML tools, compute power, and clinical expertise. These elements are now aligned, enabling faster breakthroughs.
Where are the biggest time-saving opportunities?
Keeping patient data at the center of the process shortens timelines and reduces failures.
How can proof-of-concept be accelerated?
Repurposing clinically safe drugs allows rapid validation in preclinical and early clinical trials.
More Topics
- AI in Patient Care
- AI in the Healthcare Industry
- AI and Medical Innovation
- Healthcare Ethics and Policy
Keep Exploring
About the Series
AI and Healthcare—with Mika Newton and Dr. Sanjay Juneja is an engaging interview series featuring world-renowned leaders shaping the intersection of artificial intelligence and medicine.
Dr. Sanjay Juneja, a hematologist and medical oncologist widely recognized as “TheOncDoc,” is a trailblazer in healthcare innovation and a rising authority on the transformative role of AI in medicine.
Mika Newton is an expert in healthcare data management, with a focus on data completeness and universality. Mika is on the editorial board of AI in Precision Oncology and is no stranger to bringing transformative technologies to market and fostering innovation.